<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Invasive disease-free survival, according to recurrence score and treatment (intention-to-treat population)* in patients with one to three positive axillary lymph nodes</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Invasive disease-free survival, according to recurrence score and treatment (intention-to-treat population)* in patients with one to three positive axillary lymph nodes</h1>
<div class="graphic"><div class="figure"><div class="ttl">Invasive disease-free survival, according to recurrence score and treatment (intention-to-treat population)* in patients with one to three positive axillary lymph nodes</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Recurrence-score category and type of therapy</td> <td class="subtitle1">Number of participants</td> <td class="subtitle1">Invasive disease-free survival at 5 year<br/> (percent)</td> <td class="subtitle1">Hazard ratio for recurrence<br/> (95% CI)<sup>¶</sup></td> </tr> <tr> <td class="subtitle2_left" colspan="4">Premenopausal women</td> </tr> <tr> <td>≤10, endocrine only</td> <td class="centered">174</td> <td class="centered">92.4±2.2</td> <td class="centered">0.47 (0.18-1.20)</td> </tr> <tr> <td>≤10, chemoendocrine</td> <td class="centered">151</td> <td class="centered">96.6±1.7</td> <td class="centered"> </td> </tr> <tr> <td>11 to 15, endocrine only</td> <td class="centered">277</td> <td class="centered">93.3±1.7</td> <td class="centered">0.68 (0.33-1.37)</td> </tr> <tr> <td>11 to 15, chemoendocrine</td> <td class="centered">287</td> <td class="centered">95.5±1.4</td> <td class="centered"> </td> </tr> <tr> <td>16 to 20, endocrine only</td> <td class="centered">254</td> <td class="centered">83.8±2.6</td> <td class="centered">0.57 (0.35-0.94)</td> </tr> <tr> <td>16 to 20, chemoendocrine</td> <td class="centered">269</td> <td class="centered">91.5±1.9</td> <td class="centered"> </td> </tr> <tr> <td>21 to 25, endocrine only</td> <td class="centered">118</td> <td class="centered">85.2±3.6</td> <td class="centered">0.63 (0.30-1.31)</td> </tr> <tr> <td>21 to 25, chemoendocrine</td> <td class="centered">121</td> <td class="centered">92.4±2.8</td> <td class="centered"> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Women ≤50 years</td> </tr> <tr> <td>≤10, endocrine only</td> <td class="centered">145</td> <td class="centered">91.0±2.6</td> <td class="centered">0.31 (0.10-0.94)</td> </tr> <tr> <td>≤10, chemoendocrine</td> <td class="centered">135</td> <td class="centered">97.9±1.5</td> <td class="centered"> </td> </tr> <tr> <td>11 to 15, endocrine only</td> <td class="centered">247</td> <td class="centered">93.1±1.8</td> <td class="centered">0.71 (0.33-1.51)</td> </tr> <tr> <td>11 to 15, chemoendocrine</td> <td class="centered">235</td> <td class="centered">95.4±1.6</td> <td class="centered"> </td> </tr> <tr> <td>16 to 20, endocrine only</td> <td class="centered">227</td> <td class="centered">85.1±2.6</td> <td class="centered">0.58 (0.33-1.00)</td> </tr> <tr> <td>16 to 20, chemoendocrine</td> <td class="centered">224</td> <td class="centered">92.2±2.0</td> <td class="centered"> </td> </tr> <tr> <td>21 to 25, endocrine only</td> <td class="centered">107</td> <td class="centered">80.0±4.3</td> <td class="centered">0.56 (0.27-1.17)</td> </tr> <tr> <td>21 to 25, chemoendocrine</td> <td class="centered">98</td> <td class="centered">90.0±3.6</td> <td class="centered"> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Postmenopausal women</td> </tr> <tr> <td>≤10, endocrine only</td> <td class="centered">434</td> <td class="centered">92.7±1.4</td> <td class="centered">0.72 (0.44-1.18)</td> </tr> <tr> <td>≤10, chemoendocrine</td> <td class="centered">434</td> <td class="centered">92.7±1.4</td> <td class="centered"> </td> </tr> <tr> <td>11 to 15, endocrine only</td> <td class="centered">454</td> <td class="centered">95.8±1.0</td> <td class="centered">1.30 (0.88-1.92)</td> </tr> <tr> <td>11 to 15, chemoendocrine</td> <td class="centered">524</td> <td class="centered">93.5±1.2</td> <td class="centered"> </td> </tr> <tr> <td>16 to 20, endocrine only</td> <td class="centered">525</td> <td class="centered">90.8±1.5</td> <td class="centered">0.91 (0.57-1.43)</td> </tr> <tr> <td>16 to 20, chemoendocrine</td> <td class="centered">454</td> <td class="centered">93.2±1.3</td> <td class="centered"> </td> </tr> <tr> <td>21 to 25, endocrine only</td> <td class="centered">451</td> <td class="centered">93.2±1.3</td> <td class="centered">1.13 (0.75-1.70)</td> </tr> <tr> <td>21 to 25, chemoendocrine</td> <td class="centered">255</td> <td class="centered">84.8±2.5</td> <td class="centered"> </td> </tr> <tr> <td class="subtitle2_left" colspan="4">Women &gt;50 years</td> </tr> <tr> <td>≤10, endocrine only</td> <td class="centered">463</td> <td class="centered">93.1±1.3</td> <td class="centered">0.78 (0.48-1.26)</td> </tr> <tr> <td>≤10, chemoendocrine</td> <td class="centered">472</td> <td class="centered">95.5±1.0</td> <td class="centered"> </td> </tr> <tr> <td>11 to 15, endocrine only</td> <td class="centered">554</td> <td class="centered">93.6±1.1</td> <td class="centered">1.22 (0.83-1.79)</td> </tr> <tr> <td>11 to 15, chemoendocrine</td> <td class="centered">577</td> <td class="centered">91.2±1.4</td> <td class="centered"> </td> </tr> <tr> <td>16 to 20, endocrine only</td> <td class="centered">481</td> <td class="centered">92.1±1.3</td> <td class="centered">0.86 (0.56-1.32)</td> </tr> <tr> <td>16 to 20, chemoendocrine</td> <td class="centered">496</td> <td class="centered">92.8±1.3</td> <td class="centered"> </td> </tr> <tr> <td>21 to 25, endocrine only</td> <td class="centered">266</td> <td class="centered">86.9±2.3</td> <td class="centered">1.17 (0.77-1.76)</td> </tr> <tr> <td>21 to 25, chemoendocrine</td> <td class="centered">246</td> <td class="centered">81.8±2.7</td> <td class="centered"> </td> </tr> </tbody></table></div><div class="graphic_footnotes">IDFS: invasive disease-free survival; SE: standard error.<br/>
	
	* Plus–minus values are means ±SE.<br/>
	
	¶ A hazard ratio of less than 1 indicates a higher recurrence rate with endocrine therapy only than with chemoendocrine therapy.</div><div class="graphic_reference">From: Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene assay to inform benefit in node-positive breast cancer. N Engl J Med 2021; 385:2336. Copyright © 2021 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.</div><div id="graphicVersion">Graphic 134596 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
